Business Overview

ArchiMed completed its acquisition of a majority stake in the Strasbourg-based transfection specialist, Polyplus-transfection® SA, in July 2016. Polyplus-transfection® is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bio-production and therapeutics.

Headquartered in Illkirch, outside Strasbourg in France, Polyplus-transfection® was founded in 2001 as a spin-off from the Genetic Chemistry Laboratory - Faculty of Pharmacy, University of Strasbourg. The company has a global reputation in its niche market following the pioneering role of its main founder, Prof. Jean-Paul Behr, in the development of a polymer based reagent, PEI (Polyethylenimine), for use in transfection. Key former members from Prof. Behr’s academic lab continue to drive product innovation at Polyplus-transfection®.

Polyplus-transfection® is ISO 9001-certified since 2002 and supplies its wide range of reagents for the transfection of genes, oligonucleotides and siRNA through a worldwide distributor network. Polyplus-transfection® reagents are involved in a growing number of clinical trials worldwide.

A first significant round of financing was closed in 2004 with venture capital and the company reached profitability in 2013. Polyplus-transfection® intends now to continue its strong growth with the support of new equity partner ArchiMed, driven by accelerated product innovation and increased market penetration in selected geographies. The transfection market’s growth will be supported by the increased use of biologics based therapeutics.


2001 → Polyplus-transfection® founded as a spin-off from University of Strasbourg
2001 → Launch of jetPEI® for in vitro DNA transfection
2001 → Launch of in vivo-jetPEI® for the delivery of nucleic acids in vivo
2002 → ISO-9001 certification
2004 → First significant financing round involving venture capital
2006 → Launch of INTERFERin® for siRNA transfection
2006 → Opening of US subsidiary in New York
2007 → First cGMP batch of a Polyplus-transfection® reagent supplied for a clinical trial
2009 → Launch of jetPRIME® for gene expression research
2012 → Launch of PEIpro® for virus production
2013 → Polyplus-transfection® returns to profitability
2014 → Launch of FectoPRO® for protein production
2016 → Launch of PEIpro-HQ® for virus production
2016 → ArchiMed completes its acquisition of a majority stake in Polyplus-transfection®
2016 → Launch of jetMESSENGER™ for transfection of mRNA in hard to transfect cells